Hikma And Richter Move Ahead With US Denosumab Filing

Marks Entry Of Hikma Into US Biosimilars Arena

 
• By Dave Wallace
  
Hikma is getting its ducks in a row amid a crowded denosumab market (Shutterstock)

More from Deals

More from Biosimilars